Ipsogen to present breast cancer program results at the upcoming 96th AACR annual meeting

Main Category: Breast Cancer
Article Date: 30 Mar 2005 - 12:00 PDT

email to a friend   printer friendly   opinions  

Marseille, France, March 30, 2005 - Ipsogen SAS, a molecular diagnostic company developing tests to improve disease management of cancer patients, announced today that results concerning its breast cancer program have been selected for presentation in a symposium session at the 2005 AACR Annual Meeting in Anaheim, California.

The abstract titled "Utilisation of microarray technology to refine molecular classes and improve clinical management of breast cancer," is available on the AACR website (http://www.aacr.org; abstract number: 2628) and an oral presentation has been scheduled on Monday, April 18, 2005 at 1:00 PM. Further results from this program will be separately published in a peer reviewed journal.

The results concern several gene expression signatures refining molecular classes of breast cancer. Utilisation of these signatures together with standard clinical parameters provides a unique combination discriminating patients responding to standard anthracycline chemotherapy. The test was validated in an independent cohort with patient samples from distinct clinical sites. Ipsogen will also release data concerning translation of these results to its Breast Cancer ProfileChipT, a simple diagnostic device allowing straightforward utilisation of gene signatures in clinical pathology laboratories. The study represents part of a research program Ipsogen is conducting with the Institut Paoli-Calmettes (Marseille, France) and in partnership with major French and US centres.

Based on these findings and ongoing clinical studies, Ipsogen believes there is potential for applying this test to identify patients, at diagnosis, with favorable outcome under standard anthracyclines chemotherapy to avoid unnecessary intensification.

About Ipsogen

IPSOGEN is an emerging biotechnology company utilising advanced technologies to analyse gene expression and to improve the disease management of cancers. IPSOGEN addresses two main markets: (i) The molecular diagnosis of cancer (i.e.; leukaemia, lymphomas, breast cancer) to provide innovative diagnostic tools to clinical centres; (ii) the optimisation of discovery and development of anti cancer drugs, to provide pharmaceutical companies with high value information at the pre-clinical and clinical stages, and accelerate drug development through biomarker discovery and validation. Headquartered in Marseille, France, IPSOGEN has global partnerships and markets its products worldwide.

This press release contains "forward-looking statements" as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Ipsogen SAS does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Ipsogen SAS, among others, the extent to which Ipsogen's technology platform can be used in large scale gene expression analysis, uncertainty of market acceptance of Ipsogen's technologies or ability to compete against existing technologies.

CONTACTS
Ipsogen: Vincent Fert, Chief Executive Officer - Tel +33 4 91293090 -
fert@ipsogen.com

Global Headquarters
Ipsogen
Luminy Biotech Entreprises
Case 923 - 163 Ave de Luminy
13288 Marseille
France
Tel: +33 4 91 29 30 90
Fax: +33 4 91 29 30 99
infos@ipsogen.com

North America - Oncodiagnostics
Ipsogen, Inc
83 Maple Avenue
Windsor
Connecticut 06095
USA
Tel: +1 860 298 0234
Fax: +1 860 298 8586
infos@ipsogen.com

http://www.ipsogen.com

• Additional
• References
• Citations